Login to Your Account



MDCO sits tight on MILANO-PILOT after 'inconclusive' interim analysis

By Marie Powers
News Editor

Wednesday, August 31, 2016

"The more technical explanation is not achieving a pre-specified boundary condition for stopping the trial early," Clive Meanwell, CEO of The Medicines Co. (MDCO), told BioWorld Today.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription